ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,587.00
0.23%
S&P ASX All Technology
2,972.40
0.12%
Brent Oil
83.755
0.26%
US Dollar vs AUD
1.52509
-0.39%
Bitcoin
59,101.47
1.48%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Oncocyte Corporation (OCX)

  7. Oncocyte Corporation (OCX) News

OCX Oncocyte Corporation

2.56
0.01 (0.39%)
Last Updated: 02:55:13
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Oncocyte Corporation OCX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.01 0.39% 2.56 02:55:13
Open Price Low Price High Price Close Price Previous Close
2.53 2.48 2.58 2.55
more quote information »

Recent News

Date Time Source Heading
12/4/202420:00GLOBEOncocyte Reports Full Year 2023 Financial Results
12/4/202411:46GLOBEOncocyte Corporation Announces $15.8 Million Private..
12/4/202407:30GLOBEOncocyte and Bio-Rad Partner on Global Launch of Transplant..
10/4/202406:05GLOBEOncocyte to Announce Fourth Quarter and Full Year 2024..
24/1/202408:39EDGAR2Form 8-K - Current report
17/1/202400:00GLOBEOncocyte to Present at the Sequire Investor Summit in Puerto..
07/12/202300:00GLOBEOncocyte Begins FDA Submissions Process for VitaGraft..
10/11/202309:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202323:05EDGAR2Form 8-K - Current report
09/11/202323:00GLOBEOncocyte Reports Third Quarter 2023 Financial Results
03/11/202323:30GLOBEOncocyte to Announce Third Quarter 2023 Financial Results
13/10/202307:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202307:48EDGAR2Form 8-K/A - Current report: [Amend]
06/10/202307:05EDGAR2Form 8-K - Current report
20/9/202323:00EDGAR2Form 8-K - Current report
29/8/202306:05EDGAR2Form 8-K - Current report
18/8/202308:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202306:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202321:05EDGAR2Form 8-K - Current report
25/7/202323:08GLOBEVitaGraft Kidney Expands Utility in Recurrent Primary..
25/7/202307:28EDGAR2Form 8-K - Current report
25/7/202303:35GLOBEOncocyte Announces 1-For-20 Reverse Stock Split
22/7/202307:16EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
14/7/202320:03EDGAR2Form 8-K - Current report
11/7/202301:20EDGAR2Form DEF 14A - Other definitive proxy statements
04/7/202308:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/7/202306:14EDGAR2Form PRE 14A - Other preliminary proxy statements
30/6/202306:05EDGAR2Form 8-K - Current report
27/6/202322:30GLOBEOncocyte Begins Manufacturing Transplant Blood Test
11/5/202322:00GLOBEOncocyte Reports First Quarter 2023 Financial Results

Your Recent History

NASDAQ
OCX
Oncocyte
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved